Scpharmaceuticals (SCPH) Rating Lowered to Hold at Zacks Investment Research

Scpharmaceuticals (NASDAQ:SCPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

SCPH has been the topic of several other reports. Leerink Swann lowered shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $12.00 to $5.00 in a report on Wednesday, January 30th. Svb Leerink lowered shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 30th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Scpharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.50.

Shares of SCPH stock opened at $2.82 on Thursday. Scpharmaceuticals has a 1 year low of $2.44 and a 1 year high of $15.70. The company has a market cap of $46.08 million, a PE ratio of -1.77 and a beta of 1.18. The company has a current ratio of 13.77, a quick ratio of 13.77 and a debt-to-equity ratio of 0.10.

Scpharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Thursday, March 21st. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.17. Research analysts predict that Scpharmaceuticals will post -2.07 EPS for the current year.

In other Scpharmaceuticals news, major shareholder Ra Capital Healthcare Fund Lp acquired 389,862 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were acquired at an average cost of $2.70 per share, for a total transaction of $1,052,627.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.80% of the company’s stock.

A hedge fund recently raised its stake in Scpharmaceuticals stock. JPMorgan Chase & Co. lifted its stake in shares of Scpharmaceuticals Inc (NASDAQ:SCPH) by 1,268.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,664 shares of the company’s stock after acquiring an additional 21,008 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Scpharmaceuticals worth $133,000 at the end of the most recent quarter. 42.24% of the stock is owned by institutional investors.

About Scpharmaceuticals

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Further Reading: Different Options Trading Strategies

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit